Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Zacks Investment Research, Inc.
CHICAGO, Feb. 21, 2013 /PRNewswire/ -- Zacks Equity Research highlights Valmont Industries (NYSE:VMI) as the Bull of the Day and Quest Diagnostics (NYSE:DGX) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Novartis (NYSE:NVS), Abbott (NYSE:ABT) and Eli Lilly (NYSE:LLY).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
Valmont Industries (NYSE:VMI) is primarily engaged in the production of fabricated metal products, metal and concrete pole and tower structures and mechanized irrigation systems in the U.S. and abroad.
Customers and end-users of Valmont's products include state and federal governments, contractors, utility and telecommunication companies, manufacturers of commercial lighting fixtures, large farms as well as the general manufacturing sector.
Roughly 45% of total sales last year were either achieved in markets or produced by manufacturing plants outside of North America. The company has diversified geographically to over 100 countries.
In Valmont's fourth-quarter 2012 earnings report last week, the company posted EPS of $2.43 per share, outstripping the Zacks Consensus Estimate of $2.24 while declining from the prior-year quarter's earnings of $4.33 per share.
While profit slid roughly 43% year over year to $65 million in the reported quarter, the year-ago quarter's profit was boosted by one-time benefits associated with the reorganization of the company's legal structure. Barring that benefit, earnings were $1.83 per share a year ago.
Quest Diagnostics, a leading provider of medical diagnostic testing services, reported a lackluster fourth quarter 2012 on January 23 with adjusted EPS of $1.01, down 15.8% year over year, missing the Zacks Consensus Estimate by $0.05
Fourth quarter results for Quest Diagnostics (NYSE:DGX) were of particular concern when seen from the top line. Year over year sales declined 4% primarily due to 4.4% drop in diagnostic information services revenues that accounts for over 90% of total revenues of the company.
Adjusted operating margin in the quarter contracted 232 basis points (bps) to 15.98%. Additionally, analysts are concerned about the company guidance for 2013 given market and competitive challenges. Quest Diagnostic's expected revenue growth for the upcoming fiscal quarter is to remain within a band as low as 0% to 1%, missing the Zacks Consensus Estimate of $7.5 billion that represents annualized growth rate of 1.4%.
Latest Posts on the Zacks Analyst Blog:
Label Expansion for Novartis Drug
Novartis (NYSE:NVS) recently announced that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for an additional indication.
Zortress is now approved for the prophylaxis of organ rejection in adults undergoing a liver transplant.
The approval was based on results from a phase III randomized study, which was conducted in 719 liver transplant patients starting 30 days post-transplant. The study spanned over 12 months.
Zortress reported revenues of $210 million in 2012, up 20% year over year driven by robust demand.
We note that Zortress is already approved in the US for the prophylaxis of organ rejection in adult patients undergoing kidney transplant.
The approval for the new indication makes Zortress the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US. We expect that the recent approval will further boost Zortress sales.
We remind investors that everolimus was approved by EU for use in adult liver transplant patients in the fourth quarter of 2012 under the trade name Certican.
Certican is already approved in more than 90 countries namely Chile, Philippines and Argentina to prevent organ rejection for renal and heart transplant patients. In most EU member countries, Certican is also approved in kidney and heart transplantation.
Novartis has also licensed Zortress to Abbott (NYSE:ABT) and sub-licensed to Boston Scientific for use in drug-eluting stents.
Currently, Novartis carries a Zacks Rank #3 (Hold). Large-cap pharma companies that currently look better-positioned include Eli Lilly (NYSE:LLY), a Zacks Rank #2 (Buy) stock.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
©2012 PR Newswire. All Rights Reserved.